The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksADAM.L Regulatory News (ADAM)

  • There is currently no data for ADAM

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Proposed New Investment

14 Jan 2019 07:00

RNS Number : 9795M
Adamas Finance Asia Limited
14 January 2019
 

ADAMAS FINANCE ASIA LIMITED

("ADAM" or the "Company") 

PROPOSED NEW INVESTMENT

Adamas Finance Asia Limited ("ADAM" or the "Company"), the London quoted pan-Asian diversified investment vehicle, is pleased to announce a proposed new investment in PharmaJet Inc ("PharmaJet") through a convertible bond investment (the "CB"). PharmaJet has developed innovative needle-free injectors which have received United States FDA marketing clearance, CE Mark and World Health Organisation PQS certification to deliver medications and vaccines.

PharmaJet is in a partnership with Mundipharma Pte Ltd ("Mundipharma"). This distribution relationship provides the company with access to a significant number of markets to distribute its needle-free injector technology.

PharmaJet's latest round of financing is targeting to raise between USD12M to USD20M for expansion of its business, particularly focused on Asia, and a potential Initial Public Offering ("IPO"). As the lead investor, ADAM intends to subscribe up to USD5M in the PharmaJet Convertible Bond offering. ADAM has entered into a non-binding term sheet and finalisation of the investment is subject to final legal documentation. The CB has been structured with a 4-year maturity and an annual coupon of 10% (6% cash and 4% Payment-in-Kind). The bond will be drawn in tranches with the first tranche provided subject to the satisfaction of certain conditions including completion of legal due diligence and execution of binding documentation. Once issued, the bond is convertible at the discretion of its holders at a 40% discount to a pre-money valuation established by any 'liquidity' event which would include an IPO of PharmaJet.

The company is contemplating an IPO in Singapore and/or the NASDAQ in due course and subject to market conditions.

The Directors believe that this proposed investment in PharmaJet is an attractive opportunity to participate in the healthcare sector through products that have global reach and a high relevance to Asian markets.

ADAM's Chairman, John Croft, commented on the new investment:

"We are very excited with this proposed new investment in the medical devices sector which is experiencing rapid growth, particularly in Asia. PharmaJet has developed and is marketing one of the leading needle-free injection solutions on the market which competes with traditional needle-syringe delivery devices. This investment represents another example of the attractive opportunities available to ADAM in capturing fundamental growth driven by Asia via a structured instrument which will provide income and potential capital gain."

As this investment is subject to the completion of legally binding documentation, amongst other conditions, a further update will be provided in due course.

 

 

UPDATE ON FORTUNE INSIGHT PLACEMENT

Further to the Company's update in its interim results regarding the subscription of USD12.6M by Fortune Insight Limited ("Fortune") following the sale of the Company's holding in Global Pharm Holdings Group Inc. to Fortune, the Company is awaiting the subscription funds and will provide an update in due course.

 

Enquiries:

 

Adamas Finance Asia Limited

John Croft

+44 (0) 1825 830587

WH Ireland Limited - Nominated Adviser

James Joyce

James Sinclair Ford

+44 (0) 207 220 1666

 

VSA Capital Limited - Corporate Broker

Andrew Monk

+44 (0) 20 3005 5000

Andrew Raca

Buchanan - Financial PR

Charles Ryland

Victoria Hayns

Henry Wilson

 

+44 (0) 20 7466 5000

 

About Adamas Finance Asia

ADAM is a London quoted investment company focusing on delivering long-term income and capital growth to shareholders through a diverse portfolio of pan-Asian investments. It aims to provide uncorrelated returns through a combination of capital growth and dividend income from a broad spectrum of national geographies and asset classes from the Asian Small and Medium Enterprise (SME) sector.

The company's investment manager, Harmony Capital, which has a dedicated team with real Asian expertise, is focussed on the strategy of creating income and capital growth. Harmony is sourcing predominately private opportunities and has created a strong pipeline of income generating assets from potential investments in industries such as healthcare, fintech, hospitality, IT and property across Asia. 

About Mundipharma

Mundipharma, established in 1952 and headquartered in Singapore, is a global network of companies which share a common goal of identifying and accelerating the development of medicines which add value to patients and healthcare providers globally. Mundipharma employs over 8,600 people and generated annual revenues in excess of USD3.4 billion.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
MSCCKQDQABKKQDD
Date   Source Headline
13th Jan 20215:23 pmRNSSEDOL Code Update
13th Jan 20217:00 amRNSConfirmation of Change of Company Name
11th Jan 20215:17 pmRNSDirector Dealings
31st Dec 202011:00 amRNSPlacing Update
14th Dec 20208:08 amRNSChange of Auditor
10th Dec 202010:17 amRNSAppointment of new Broker
1st Dec 202011:52 amRNSDirectors Dealings
19th Nov 20207:00 amRNSUnaudited NAV and Portfolio Update for Q3 30 Sept
2nd Nov 202012:21 pmRNSPlacing Update
16th Oct 20203:57 pmRNSHolding(s) in Company
16th Oct 20203:57 pmRNSHolding(s) in Company
16th Oct 20203:55 pmRNSHolding(s) in Company
16th Oct 20203:53 pmRNSHolding(s) in Company
9th Oct 20202:49 pmRNSHolding(s) in Company
7th Oct 20207:00 amRNSResult of Open Offer & Placing & Share Allotment
1st Oct 20207:00 amRNSOpen Offer and Placing Update and Portfolio Update
22nd Sep 20202:12 pmRNSShare Buyback
18th Sep 20204:14 pmRNSOpen Offer and Placing Update
10th Sep 20205:23 pmRNSOpen Offer and Placing Update
7th Sep 20203:10 pmRNSShare Buyback
7th Sep 20207:00 amRNSOpen Offer and Placing Update
2nd Sep 20203:32 pmRNSOpen Offer and Placing Update
28th Aug 20207:00 amRNSAsset Overview: FLMH
24th Aug 20207:00 amRNSResult of Open Offer
21st Aug 20208:50 amRNSInterim Results for the six months ended 30 Jun 20
20th Aug 20201:39 pmRNSHolding(s) in Company
20th Aug 20201:38 pmRNSHolding(s) in Company
19th Aug 20207:00 amRNSAppointment of Non-Executive Director
18th Aug 20208:51 amRNSShare Buyback Programme
17th Aug 20207:22 amRNSResult of 2020 AGM
17th Aug 20207:20 amRNSResult of 2019 AGM
12th Aug 20208:26 amRNSAsset Overview: Meize Energy
7th Aug 20207:00 amRNSUpdate on Future Metal Holdings
5th Aug 20203:07 pmRNSResult of General Meeting
5th Aug 20207:00 amRNSFuture Metal Holdings Limited: Asset Overview
22nd Jul 20207:00 amRNSNotice of 2019 and 2020 Annual General Meetings
20th Jul 202010:26 amRNSHolding(s) in Company
17th Jul 20207:00 amRNSOpen Offer, Placing and Notice of GM
3rd Jul 20209:09 amRNSUpdate on Future Metal Holdings Limited
9th Jun 20204:00 pmRNSAGM Update
3rd Jun 20207:00 amRNSUnaudited Net Asset Value and Portfolio Update
1st Jun 20207:58 amRNSResearch Note and Interview Published
18th May 20207:00 amRNSFinal Results
11th May 20207:00 amRNSSecond Subscription to Corporate Bond
3rd Mar 20202:09 pmRNSPlacing of Shares with a Syndicate
5th Feb 20207:00 amRNSResearch Note and Interview Published
27th Dec 20197:00 amRNSFuture Metal: Production Commenced and Update
23rd Dec 20197:00 amRNSShare Buyback
15th Nov 20197:00 amRNSCompletion of SPA with Infinity Capital Group
14th Nov 20196:24 pmRNSPostponement of Annual General Meeting

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.